Leqvio (Inclisiran) and Diphenhydramine Interaction: Safety, Risks, and Clinical Guidance

Leqvio (inclisiran) is a small interfering RNA (siRNA) injection, FDA-approved as an adjunct to diet and maximally tolerated statin therapy for adults with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who need additional LDL-cholesterol lowering. Diphenhydramine (brand name Benadryl and many store-brand generics) is an over-the-counter first-generation antihistamine used for allergic symptoms, itching, and occasional sleeplessness. These two drugs are cleared by different biological systems, and no pharmacokinetic drug interaction between them has been described in the inclisiran prescribing information or in published pharmacology literature reviewed for this article.

That single fact is the whole clinical answer for most readers. The more useful discussion is about what "no interaction" does and does not mean, and what still needs individual judgment: diphenhydramine's own risks in older adults, and the fact that inclisiran's official label does not enumerate a drug-interaction study program the way small-molecule drugs typically do.

The core answer, stated plainly

Inclisiran is degraded by tissue nucleases after it does its job silencing PCSK9 messenger RNA in the liver; it does not depend on cytochrome P450 (CYP) enzymes for clearance. Diphenhydramine is metabolized substantially through CYP2D6, with lesser contributions from other CYP isoforms. Because inclisiran never passes through the CYP pathways that diphenhydramine affects, there is no shared metabolic route for these two drugs to compete over, and the FDA-approved inclisiran label states that no clinically significant drug-drug interaction studies identified a signal (FDA label, accessdata.fda.gov). This is a mechanistic and regulatory-label conclusion, not a claim that every possible combination has been formally trialed together.

Why patients and clinicians ask about this pairing

People taking Leqvio are often also managing seasonal allergies, occasional insomnia, or a cold, and diphenhydramine is one of the most common OTC drugs on the market. Many general drug-interaction checkers flag diphenhydramine broadly because it is a moderate CYP2D6 inhibitor that matters for drugs like codeine, tamoxifen, or metoprolol. Readers who see those warnings elsewhere reasonably wonder whether the same caution extends to inclisiran. It does not, because inclisiran is not a CYP substrate to begin with.

What is established

• Inclisiran's stated mechanism is siRNA-mediated silencing of PCSK9 mRNA in hepatocytes, delivered via a GalNAc conjugate that targets the asialoglycoprotein receptor. The FDA label describes elimination as occurring through nuclease-mediated degradation rather than CYP450 oxidation or conjugation (FDA label).
• The FDA-approved inclisiran label does not list diphenhydramine, antihistamines as a class, or CYP2D6 substrates/inhibitors among drugs of concern, and states that no clinically significant interactions were identified in the clinical program.
• Diphenhydramine is well documented in pharmacology references as a CYP2D6-metabolized drug with anticholinergic and sedating properties that are independent of any concurrent cardiovascular medication.
• Diphenhydramine carries recognized risks in adults 65 and older (sedation, falls, urinary retention, confusion) that are described in geriatric prescribing guidance (the AGS Beers Criteria framework). Those risks exist regardless of whether the patient is also taking inclisiran.

What is pharmacologically plausible but not specifically studied

• Injection-site reactions are a known and relatively common adverse effect of inclisiran. Some clinicians have informally suggested that an antihistamine could blunt a histamine-mediated component of local redness or itching at the injection site. This is a plausible pharmacologic extrapolation from how antihistamines work generally, not a tested or label-supported practice. No controlled data on premedicating with diphenhydramine before an inclisiran injection were identified for this article, and this should be treated as an open question rather than a recommendation.
• Both drugs bind plasma albumin to some degree. At the concentrations reached with standard inclisiran dosing and typical diphenhydramine doses, protein-binding displacement severe enough to matter clinically is not a plausible mechanism, but this article did not identify a dedicated study ruling it out numerically.

What is not established

• Whether inclisiran and diphenhydramine were specifically co-administered and tracked as a distinct subgroup in the pivotal ORION clinical trial program is not something this article can confirm from the sources reviewed. Trial populations for cardiovascular drugs commonly permit OTC medication use, but published trial reports typically summarize adverse events overall rather than breaking them out by every concomitant OTC drug. Readers should not treat "used in a large trial population" as equivalent to "specifically tested together."
• Precise adverse-event rates, exact trial enrollment numbers, and specific percentage reductions in LDL-C attributed to inclisiran are stated in the FDA label and in the original trial publications, but the identifiers carried in earlier drafts of interaction content like this one are not verified here. Anyone who needs an exact figure (injection-site reaction rate, percent LDL-C reduction, trial N) should pull it directly from the current FDA label or the primary trial publication rather than relying on a secondary summary.

Evidence hierarchy behind this conclusion

1. FDA-approved label (primary regulatory evidence): the inclisiran prescribing information describes its non-CYP clearance mechanism and states no clinically significant drug interactions were identified in its development program. This is the strongest and most current evidence for the "no known interaction" claim.
2. General pharmacology knowledge (textbook-level, secondary): diphenhydramine's CYP2D6-dependent metabolism and anticholinergic pharmacodynamics are well established in pharmacology references, though a specific citation was not reused here because the inherited identifier could not be verified.
3. Geriatric prescribing guidance (guideline-level): recommendations against routine diphenhydramine use in older adults come from established geriatric prescribing frameworks (the Beers Criteria concept), independent of any interaction with inclisiran.
4. Clinical trial data (ORION program): these establish inclisiran's efficacy and overall safety profile but were not confirmed here to include a dedicated diphenhydramine subgroup analysis.

Evidence-status interaction assessment

Populations that need extra thought

Adults 65 and older. The concern here is diphenhydramine itself, not any interaction with inclisiran. Sedation, anticholinergic side effects, fall risk, and cognitive effects are recognized reasons that geriatric prescribing guidance discourages routine diphenhydramine use in this age group. A second-generation antihistamine (cetirizine, loratadine, fexofenadine) is generally preferred for allergy symptoms in older adults, independent of whatever cardiovascular medications they take.

Hepatic impairment. Inclisiran exposure has been evaluated in mild hepatic impairment and increases modestly; it has not been well characterized in moderate-to-severe hepatic impairment according to the FDA label. Diphenhydramine clearance can also slow in liver disease, intensifying its sedative and anticholinergic effects. This is two independent pharmacokinetic changes happening in the same patient, not a drug-drug interaction between the two agents.

Renal impairment. The FDA label describes increased inclisiran exposure in severe renal impairment without a recommended dose adjustment. Diphenhydramine's metabolites are renally cleared as well. Again, these are parallel, independent considerations rather than a synergistic interaction mechanism.

Practical guidance

For most adults under 65 who occasionally need diphenhydramine for allergy symptoms or short-term sleep difficulty, taking it alongside a Leqvio regimen does not require special precautions, dose separation, or additional lab monitoring based on current label information. The decision about which antihistamine to use should turn on the patient's age, fall risk, cognitive status, and how sensitive they are to sedation and anticholinergic side effects, not on any interaction with inclisiran.

Chronic, nightly diphenhydramine use for sleep is generally discouraged in current sleep medicine guidance regardless of other medications, because tolerance to its sedating effect develops and anticholinergic burden accumulates. That guidance stands whether or not a patient is also on Leqvio.

When to involve a pharmacist or clinician

• Before starting or continuing regular (not occasional) diphenhydramine use, especially in anyone over 65 or with cognitive concerns.
• If diphenhydramine is being considered specifically to manage an inclisiran injection-site reaction, since this use is not established practice.
• If a patient is on multiple CYP2D6-dependent medications where diphenhydramine's inhibition could matter, even though inclisiran itself is not one of them.
• If new or worsening confusion, urinary retention, palpitations, or unusual injection-site reactions occur; these warrant a call to the prescribing clinician rather than self-management.

Evidence boundary

What is established: inclisiran and diphenhydramine use different clearance pathways, and the FDA-approved inclisiran label reports no identified clinically significant drug-drug interactions. What is plausible but unproven: using diphenhydramine to blunt injection-site symptoms. What is not established from the sources reviewed here: whether any trial specifically isolated diphenhydramine as a concomitant medication subgroup. Readers who need an exact statistic, such as a specific injection-site reaction rate or LDL-C reduction percentage, should pull it from the current FDA label or the original trial publication rather than a secondary summary, since specific figures were not independently re-verified for this draft.

References

1. U.S. Food and Drug Administration. Leqvio (inclisiran) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf

Additional claims about diphenhydramine's specific metabolic pathway, geriatric prescribing guidance details, and inclisiran trial data referenced above should be confirmed against the current diphenhydramine product label, the current AGS Beers Criteria publication, and the original ORION trial reports before being cited with precise figures. The citations carried in earlier versions of this content could not be independently verified and have been removed rather than repeated.